EGCG inhibits the expression of epidermal growth factor receptors (EGFR or ErbB) such as ErbB1 and ErbB2, which are overexpressed in breast cancer [19], especially in epidermoid carcinoma (A-431) and SK-BR3. Here, EGFR is linked to squamous cell carcinoma.